WARS1 and ovarian carcinoma: To assess the ability of the models to specifically detect AA and CRC, methylation of GALNT9, UPF3A, WARS, and LDB2 was quantified in serum from patients with lung, breast, kidney, prostate, and ovarian cancer (n = 16) (Fig. 5C, Additional file 1: Table S1).